An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Explore Dr. TamoJit Chaudhury’s expert insights on optimizing advanced urothelial carcinoma treatment, covering immunotherapy, targeted therapy, and clinical trial breakthroughs.

Speakers : Dr. Tamojit Chaudhury

Updates on the First Line Management of ALK+ NSCLC

In this webinar, a detailed discussion is done on Enhancing Outcomes in Advanced Lung Cancer

Speakers : Prof. Tony Mok

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speakers : Prof. Jessica Lin

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Join Prof. Solange Peters as she explores post-progression strategies after first-line third-generation ALK inhibitors in NSCLC.

Speakers : Prof. Solange Peters

Oropharyngeal Cancer in Relation to HPV Status

Learn about the occurrence of oropharyngeal cancer in HPV negative patients through different case presentations.

Speakers : Dr. Ashish M Kaushal

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Dr. Rohit R Pai compares Nimotuzumab plus chemoradiotherapy vs. placebo plus chemoradiotherapy in locally advanced nasopharyngeal carcinoma (LA-NPC).

Speakers : Dr. Rohit R Pai - Speaker

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

Explore the role of Nimotuzumab in Nasopharyngeal Cancer management with Dr. Abhishek Raj, focusing on targeted therapy and improved patient outcomes.

Speakers : Dr. Abhishek Raj

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Explore the benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer with Dr. Shailesh Bondarde.

Speakers : Dr Shailesh Bondarde

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Discover how CDK4/6 inhibitors extend progression-free survival (PFS) and overall survival (OS) in HR+/HER2- metastatic breast cancer (mBC) patients.

Speakers : Dr Parveen Jain

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Explore expert insights on first-line maintenance therapy for metastatic urothelial carcinoma in this panel discussion featuring Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre.

Speakers : Dr Tushar Patil ,Dr Varun Nagori ,Dr Amol Dongre


Recommended News For You

Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.

A better option for mild to moderate depression?

A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.

Study identifies new approach to protect the brain during radiation therapy

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

FDA approves Blenrep for relapsed or refractory multiple myeloma

Recommended Articles For You

Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025 

Oncological Surgery Today: Personalized, Interdisciplinary Approaches to Cancer Care 

Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access 

Precision Oncology: Tailoring Cancer Treatment for the Individual 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

2.

Cancer patients want financial screening early in care, study finds

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

November 2023, Medical Bulletin 04/.

5.

Radiation therapy for patients with breast cancer

1.

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies

2.

HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians

3.

Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia

4.

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion

5.

The latest Hematocrit: An Overview of Red Blood Cell Health 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

3.

Navigating the Complexities of Ph Negative ALL - Part X

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Navigating the Complexities of Ph Negative ALL - Part IX

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot